Terms: = Liver cancer AND GOLGA5, ret-II, 9950, ENSG00000066455, rfg5, golgin-84, Q8TBA6 AND Treatment
4 results:
1. Determination of five mTOR inhibitors in human plasma for hepatocellular carcinoma treatment using QuEChERS-UHPLC-MS/MS.
Wang T; Jin C; Jiang W; Zhao T; Xu Y; Li H
J Pharm Biomed Anal; 2023 Oct; 235():115652. PubMed ID: 37633163
[TBL] [Abstract] [Full Text] [Related]
2. Hypothyroidism has a protective causal association with hepatocellular carcinoma: A two-sample Mendelian randomization study.
Lu L; Wan B; Li L; Sun M
Front Endocrinol (Lausanne); 2022; 13():987401. PubMed ID: 36246884
[TBL] [Abstract] [Full Text] [Related]
3. Novel polymeric nanoparticles containing tanshinone IIA for the treatment of hepatoma.
Li Q; Wang Y; Feng N; Fan Z; Sun J; Nan Y
J Drug Target; 2008 Dec; 16(10):725-32. PubMed ID: 19005937
[TBL] [Abstract] [Full Text] [Related]
4. Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum.
Varghese S; Burness M; Xu H; Beresnev T; Pingpank J; Alexander HR
Ann Surg Oncol; 2007 Dec; 14(12):3460-71. PubMed ID: 17899288
[TBL] [Abstract] [Full Text] [Related]
